POLYMOX (amoxicillin) by Bristol Myers Squibb is [see microbiology ()] . Approved for infections due to susceptible strains of designated microorganisms, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of streptococcus species, the treatment of infections due to susceptible (only β-lactamase–negative) isolates of escherichia coli and 3 more indications.
Drug data last refreshed 1mo ago
[see Microbiology ()] .
Worked on POLYMOX at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Drug-Drug Interaction Between DW4421 and Amoxicillin/Clarithromycin
A Study to Investigate the Effect of Linaprazan Glurate on the Pharmacokinetics of Amoxicillin
Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection
Drug Interaction Study Between Tegoprazan, Bismuth, Amoxicillin and Clarithromycin
Oral Sulopenem Versus Amoxicillin/Clavulanate for Uncomplicated Urinary Tract Infection in Adult Women